Onvansertib is a third-generation, oral adenosine triphosphate (ATP) competitive kinase inhibitor developed to treat patients with acute myeloid leukemia (AML), particularly those who are resistant to… Read more
Onvansertib is a third-generation, oral adenosine triphosphate (ATP) competitive kinase inhibitor developed to treat patients with acute myeloid leukemia (AML), particularly those who are resistant to existing therapies. This category provides access to high-quality reference standards of Onvansertib, which are essential for pharmaceutical laboratories conducting rigorous analytical testing and method validation. The collection includes the active pharmaceutical ingredient along with relevant pharmacopeial and non-pharmacopeial impurities, as well as stable isotope labelled compounds. These materials are critical for accurate impurity profiling and quantitative analysis, enabling researchers to maintain strict quality control standards throughout the drug development and manufacturing lifecycle. By utilizing these precise standards, laboratories can ensure the consistent safety and efficacy of the drug substance during every phase of testing.